Tosseque

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Tosseque

Understanding Tosseque

Tosseque is a pharmaceutical formulation developed to address symptoms associated with various respiratory conditions. It is classified as an antitussive and expectorant medication, designed to assist in the management of coughs that are either dry or productive in nature.

Composition and Mechanism

The effectiveness of Tosseque is derived from its active components, which typically include substances aimed at reducing the sensitivity of the cough reflex and agents that facilitate the thinning of mucus.

  • Antitussive Action: One component works by acting on the cough center in the brain to suppress the urge to cough. This is particularly useful for non-productive, hacking coughs that can cause throat irritation and disrupt sleep.
  • Expectorant Action: Another component helps to decrease the viscosity of bronchial secretions. By thinning the mucus in the airways, it makes it easier for the body to expel phlegm through coughing, thereby clearing the respiratory tract.

Therapeutic Use

Tosseque is used to provide symptomatic relief for respiratory tract congestion. It is often utilized in cases of the common cold, bronchitis, or other inflammatory conditions of the respiratory system where coughing and mucus buildup are present.

The primary goal of the medication is to make the cough more efficient when it is productive and to provide comfort by reducing frequency when the cough is dry and irritating. It does not treat the underlying viral or bacterial infection but focuses on improving the patient's comfort during the recovery process.

Regulatory References

  1. DailyMed Label for Bromhexine (NIH/FDA)

What side effects are possible with Tosseque?

Possible Side Effects and Safety Information

The safety profile for Tosseque is characterized by two main areas of risk: common, less severe effects, and a low but serious risk of severe systemic reactions.

Adverse Reactions by System-Organ Class

Adverse reactions typically involve Gastrointestinal disorders (e.g., nausea, vomiting, diarrhoea, epigastric pain) and Skin and subcutaneous tissue disorders (e.g., rash, urticaria). Nervous system disorders such as headache and dizziness have also been reported. A transient rise in liver enzyme values (AST/ALT) is a very rare, documented effect.

Serious Adverse Reactions

The most clinically significant safety warnings pertain to Immune system disorders and Severe Cutaneous Adverse Reactions (SCARs). Reports include serious hypersensitivity reactions, such as anaphylactic reactions (including anaphylactic shock), angioedema, and SCARs, including erythema multiforme, Stevens-Johnson syndrome/toxic epidermal necrolysis (SJS/TEN), and acute generalized exanthematous pustulosis (AGEP). The frequency of these severe reactions is considered low but is explicitly noted in official regulatory documents, and patients should be aware of the possibility of their occurrence.

Safety Considerations and Restrictions

  • Contraindications: The medicine is contraindicated in patients with known hypersensitivity to the active substance or excipients, and in individuals with an existing peptic ulcer.
  • Special Caution: Caution is advised for patients with a history of gastroduodenal ulcers and those with bronchial asthma. Due to the mechanism of action, this medicine should not be administered concomitantly with antitussives (cough suppressants).
  • Vulnerable Populations: Administration should generally be avoided in nursing women. Caution is advised for use during pregnancy, particularly in the first trimester. Patients with rare hereditary problems of fructose intolerance should not take the liquid formulation.

Anticipated effects from the mechanism of action include an expected increase in expectoration and cough due to the thinning of mucus. The duration of therapy should not exceed seven consecutive days unless directed by a healthcare professional.

Overdose and Emergency Response

Overdose and When to Seek Help

This section outlines the officially documented overdose information for Tosseque (Bromhexine hydrochloride) as found in governmental regulatory documents.

Documented Overdose Manifestations

Regulatory reporting indicates that symptoms observed following an overdose are generally consistent with the known side effects of the medicine. These may include gastrointestinal issues such as nausea, vomiting, and stomach pains (abdominal pain). Diarrhea, headache, and dizziness have also been reported.

When to Seek Immediate Medical Attention

Urgent medical help is explicitly required in two specific scenarios, as mandated by official labeling:

  1. Suspected Overdose: In the event of an overdose or suspected overdose, the instruction is to immediately telephone a doctor, pharmacist, or the Poisons Information Centre.
  2. Severe Reactions: If any signs of a progressive skin rash or severe allergic reaction (such as difficulty breathing, or swelling of the face, lips, mouth, or throat) occur, the medicine must be discontinued immediately, and medical advice must be sought without delay. This addresses the rare, but serious, documented risk of severe cutaneous reactions.

Management and Antidote

Official documents specify that no specific antidote for Bromhexine hydrochloride has been reported in human overdose cases. Therefore, the management approach is defined as symptomatic treatment, which focuses on addressing the clinical manifestations presented.

Therapeutic Uses of Tosseque

A core therapeutic role of Tosseque is to manage symptoms related to the production of thick, tenacious mucus or phlegm, as this mucoactive therapy is applied across domains where additional symptomatic support is needed. The therapeutic role is to assist with the thinning of mucus, which supports the easing of chest congestion.

Tosseque is used in situations involving distressing symptoms associated with respiratory tract infections, acute bronchitis, and conditions characterized by periods of heightened symptoms like chronic bronchitis or COPD. It helps address symptom clusters that may become intense or disruptive due to the difficulty in expelling phlegm. The supportive action assists with improving the consistency of the phlegm, which supports its removal. This process contributes to improved comfort during periods of heightened symptoms, which generally helps patients cope more steadily with difficult episodes.


Quick Fact: Relief for Viscous Phlegm

Tosseque is applied in clinical settings that involve acute or unstable symptom patterns, commonly used when short-term symptomatic assistance is needed to facilitate the clearance of accumulated mucus, particularly during exacerbations of chronic lung conditions or acute respiratory illnesses.

Regulatory References

  1. Australian Therapeutic Goods Administration

Eligibility and Restrictions for Use

Official Eligibility and Restrictions for Tosseque

Regulatory labeling establishes clear criteria for who can and cannot use Tosseque (Bromhexine hydrochloride).

Contraindicated Populations (Must Not Use)

Category Regulatory Status
Hypersensitivity Contraindicated for patients with known allergy to bromhexine or excipients.
Active Ulceration Contraindicated in cases of active gastroduodenal ulcer.
Hereditary Intolerance Contraindicated with rare hereditary problems like fructose intolerance (due to excipients).

Age-Related Eligibility

  • Adults and Adolescents (12+): Use is generally permitted under standard labeled conditions.
  • Children 6 to 11 Years: Use is permitted, but typically restricted to only on the advice of a doctor or pharmacist for over-the-counter products.
  • Children Under 6 Years: Do not use is the explicit regulatory instruction for oral liquids/tablets in many regions.

Condition-Based Restrictions (Use with Caution)

Patients with severe renal impairment or severe hepatic impairment are restricted to use only with caution and under medical supervision, as the clearance of the drug or its metabolites may be reduced. Caution is also advised for patients with a history of peptic ulceration or bronchial asthma.

Pregnancy and Lactation Eligibility

  • Pregnancy: Use is generally not recommended as a precautionary measure, especially during the first trimester.
  • Lactation: Should not be used during breast-feeding due to potential risk and insufficient data on excretion into human milk.

What should I know about interactions with other medicines?

Tosseque (Bromhexine hydrochloride) has a regulatory interaction profile characterized by low general interaction risk. Official regulatory documentation indicates that no clinically relevant unfavorable interactions with other medicinal products have been reported.

Co-Administration Restrictions

The most significant restriction concerns specific pharmacodynamic interactions. Co-administration with antitussives (cough suppressants) is advised against, as the simultaneous use of a drug that suppresses the cough reflex may lead to the accumulation of secretions loosened by Tosseque, a condition known as stagnant phlegm. Similarly, official labels caution against combining Tosseque with drugs that reduce bronchial secretions, such as anticholinergics, because this may counteract the desired mucolytic effect.

Documented Exposure Modification

An officially documented interaction involves specific antibiotics. Co-administration of Tosseque with amoxycillin, erythromycin, oxytetracycline, cefuroxime, or doxycycline results in an increase in the concentration of the antibiotic specifically within the bronchopulmonary secretions. This is a documented pharmacodynamic effect on the co-administered drug.

General Interaction Context

The product label confirms that there are no mandated timing rules for administration; Tosseque may be taken with or without food. While there are no documented drug-drug interactions involving changes to Tosseque's plasma levels, clearance of the medicine or its metabolites may be reduced in patients with severe hepatic or renal impairment, which is a documented population-specific consideration.

Mechanism of Action

How Tosseque Works (Mechanism of Action)

Tosseque exerts its pharmacodynamic action through two primary mechanistic domains that modulate respiratory tract secretions. The drug acts as a mucolytic agent by chemically and enzymatically disrupting the acidic mucin fibers that form the structural network of mucus. This fragmentation of high-molecular-weight polymers leads to an alteration in rheological properties, specifically reduced viscosity and elasticity, of the secretions.

Concurrently, Tosseque functions as a secretagogue, stimulating the production of low-viscosity serous fluid from submucosal glands lining the bronchial tree. This action is paired with a direct secretomotor effect, increasing the beat frequency and coordination of the cilia in the airways . The resulting reduction in adhesion, combined with enhanced ciliary activity and fluid volume, increases the overall rate and volume of mucociliary transport, modulating the physiological process of clearance.

Dosage and Administration Information

Official Administration Guidelines for Tosseque Syrup

This information details the exact instructions for using Tosseque (Bromhexine hydrochloride syrup) as specified in official documentation. It does not contain information on therapeutic effects, safety, or side effects.


Route of Administration:

Tosseque is for Oral use only.

Dosing Schedule and Frequency

Administration is three times a day for all age groups. Dosing must be measured precisely using the provided measuring spoon or cup.

Age Group Single Dose Volume
Adults and children over 12 years 10 mL
Children 6 to 12 years 5 mL
Children 2 to 6 years 2.5 mL
Children 1 to 2 years 1.25 mL

Special Conditions and Duration of Use

The maximum recommended course of treatment is generally limited. Do not use the syrup for longer than seven consecutive days unless specifically advised by a physician. Administration for children under the age of two years must be performed only under medical supervision due to their reduced ability to clear secretions effectively.

Missed Dose and Preparation

If a dose is missed, take it as soon as it is remembered. However, if it is nearly time for the next scheduled dose, the missed dose should be skipped, and the regular dosing schedule resumed. Do not take a double dose to make up for the missed one. The syrup bottle should be shaken well before use, and the medicine may be taken with or soon after food.

Recent Clinical Evidence

Research evidence / Overview of studies for Tosseque


Research Evidence for Managing Viscous Mucus and Phlegm

The medicine was studied for its licensed use in numerous studies exploring how symptoms change over time. The study types available for this purpose include Randomized Controlled Trials and subsequent Systematic Reviews that contribute to the broader evidence landscape. Research has explored the medicine's role in conditions involving periods of heightened symptoms. The studies monitored outcomes related to the physical properties of secretions, specifically how sticky or thick the mucus is, and patient-reported outcomes describing perceived discomfort associated with phlegm clearance.

The findings describe patterns observed in the studies where researchers measured differences in patient-reported outcomes describing perceived discomfort. However, the evidence quality varies across studies; many foundational trials had sample sizes were modest and did not adhere to modern, standardized procedures. Consequently, the certainty of the evidence is considered low to moderate in scientific reviews, and long-term effects are not fully established.


Investigational Research in Other Clinical Contexts

Tosseque was studied for an entirely different research application involving a potential mechanism separate from its established mucoactive role. This involved studies focusing on episodes where symptoms become more noticeable and hard clinical outcomes in patients with viral illnesses. The study types available include Randomized Controlled Trials and follow-up Meta-analyses. Studies monitored severe clinical endpoints, including patient outcomes related to physiological strain or stress.

The data show patterns related to measured differences in clinical progression between the observed patient groups. However, the findings were mixed across various clinical trials, and the certainty remains low. Researchers reported that many of the initial trials were underpowered. This research area remains investigational and is not a licensed indication for Tosseque.


Gaps and Remaining Uncertainty in the Research Record

For the drug's primary use, follow-up durations were limited in many studies, meaning there is limited information for outcomes that occur over extended periods. Research exploring the drug's effect in certain special populations, such as children, has generally been noted to have data for certain groups remain insufficient.

Frequently Asked Questions (FAQ)

Common questions about Tosseque (FAQ)


Q: Is Tosseque a type of antibiotic or an anti-inflammatory?

According to official drug classifications, Tosseque is a mucolytic agent and a secretolytic agent. This means its primary function is to thin out and loosen mucus and phlegm. It is not classified as a drug intended to fight bacterial infections (an antibiotic) or to reduce swelling (an anti-inflammatory drug).


Q: Can older adults typically use Tosseque without special concerns?

Regulatory documents establish eligibility criteria primarily based on age (restrictions for young children) and existing health conditions. For adults, use is generally permitted under standard conditions. However, official information advises caution and medical supervision for any patient who may have severe kidney or liver impairment, a condition more common in older populations.


Q: Is Tosseque safe to use during pregnancy according to the official labeling?

As a precautionary measure, the official regulatory labeling generally states that use during pregnancy is not recommended. This recommendation is especially relevant during the first three months. Consultation with a healthcare professional is noted when considering use during pregnancy or when planning for pregnancy.


Q: If I stop taking Tosseque, what are the expected effects?

The official safety information suggests that stopping the use of this medicine without consulting a healthcare professional is not recommended. If use is discontinued prematurely, there is a possibility that the original respiratory symptoms, such as having a cough or thick phlegm, may return or worsen, according to labeling.


Q: Can Tosseque affect my ability to drive or operate machinery?

Official safety documents report that nervous system disorders, such as dizziness and headache, have been listed as possible adverse reactions. If these effects are experienced, the ability to drive or safely operate machinery could be affected. It is advisable for the user to be aware of their individual reaction to the medicine before engaging in such activities.


Q: What if I experience a rare or serious side effect?

The official safety profile reports a low risk of rare but serious adverse reactions, which include severe allergic reactions (anaphylaxis) and severe skin reactions (like Stevens-Johnson syndrome). If signs of a severe reaction occur, such as swelling of the face or throat or a spreading rash, seeking immediate professional medical attention is advised, as noted in the safety warnings.


Q: Do I need a prescription to get Tosseque, or is it over-the-counter?

In many countries, the medicine Tosseque is officially classified as an Over-the-Counter (OTC) product or a Pharmacy Medicine. This classification means it is typically available for purchase without needing a doctor's prescription.


Q: Why does the packaging say 'Black Box Warning'?

The official labeling for Tosseque does not use the specific term 'Black Box Warning' (which is primarily a U.S. regulatory term). However, regulatory documents highlight explicit warnings about the potential for Severe Cutaneous Adverse Reactions (SCARs) and severe allergic reactions, which are serious risks that require explicit attention.


Q: What happens if I accidentally miss a dose of Tosseque?

The official administration guidelines state that if a dose is missed, it should be taken right away once remembered. However, if it is already close to the time for the next scheduled dose, the missed dose should be skipped, and the regular schedule resumed. Taking a double dose to compensate for a missed one is explicitly advised against in the guidelines.


Q: Does Tosseque have a generic version available?

Tosseque is a brand name for a medicine containing the active ingredient Bromhexine hydrochloride. Since this active substance has been available for a long time, many medicines containing the identical active ingredient are available globally under different brand names or as unbranded generic preparations.


Q: Are there any specific foods I should avoid while using Tosseque?

Official product information confirms that there are no specific food-related restrictions that must be followed while taking this medicine. The drug can be taken with or without food, as there are no documented drug-food interactions that prohibit the consumption of certain items.


Q: Is it true that certain medical conditions prevent me from using Tosseque?

Yes, regulatory labeling lists a few conditions that are considered contraindications, meaning the medicine must not be used. These include having an active stomach or intestinal ulcer, a known allergy to any of the ingredients, or certain rare hereditary intolerances to excipients in the liquid formulation.


Q: Is there a risk of becoming dependent on Tosseque?

Based on official safety information and drug classification, the active substance in Tosseque is not considered to be habit-forming.


Q: Can men and women use Tosseque differently?

Official administration guidelines provide dosing instructions based on age group (e.g., adult, child) and body size, but they do not specify different dosing schedules or restrictions based on the patient's sex (male or female). Exceptions related to sex apply only to pregnancy and lactation.


Q: What is the common dosage strength that Tosseque comes in?

The syrup formulation of Tosseque is typically available with an official concentration of 0.8 milligrams of bromhexine hydrochloride per milliliter (0.8 mg/ml). Doses are measured in milliliters (mL), which determines the total amount of active substance administered.


Q: Can I crush or split the Tosseque tablet?

The product Tosseque is typically supplied as an oral solution or syrup, which is a liquid form. Therefore, instructions for crushing or splitting solid tablets or capsules do not apply to this specific formulation.


Q: What does the label mean by 'Special Population Use'?

This term refers to patient groups who require specific caution or unique regulatory consideration due to their physiological state or pre-existing conditions. Examples of Special Populations listed in the official documentation include children, pregnant or breastfeeding individuals, and those with severe liver or kidney impairment (severe organ problems).


Q: Why does Tosseque require close monitoring by a doctor?

Official safety documentation advises caution and medical supervision for patients with certain pre-existing conditions. These conditions include a history of peptic ulceration, bronchial asthma, and those with severe hepatic or renal impairment (severe liver or kidney problems).

How should Tosseque be stored and disposed of?

How to Store and Dispose of Tosseque

Tosseque (Bromhexine hydrochloride syrup) must be stored under specific environmental and container conditions to ensure its stability, as defined in official regulatory labeling.

Official Storage Requirements

Condition Requirement
Temperature Do not store above 30°C.
Protection Must be protected from light.
Container Keep in the original container and inside the outer carton.
Shelf Life Shelf life as packaged for sale is 3 years.

The medicine must also be kept out of the sight and reach of children, a requirement supported by the child-proof cap on the bottle.

Disposal

Official labeling specifies no special requirements for disposal of the unused product or waste material. Any unused or expired Tosseque should be disposed of in accordance with local regulatory waste requirements.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Tosseque found in:

A-Z Index: